CFM
PLRX icon

Catalyst Funds Management’s Pliant Therapeutics PLRX Stock Holding History

Catalyst Funds Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-59,539
Closed -$88.1K – 523
2025
Q3 		$88.1K Buy
59,539
+25,524
+75% +$38.9K 0.01% 462
2025
Q2 		$39.5K Buy
+34,015
New +$48.1K 0.01% 389

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Catalyst Funds Management's PLRX Position: Q4 2025 in Review

Catalyst Funds Management sold out of Pliant Therapeutics (PLRX) in Q4 2025, closing a stake of 59,539 shares — an estimated $88.1K sold.

Catalyst Funds Management first reported a position in PLRX in Q2 2025 and held it in 2 quarters. The position peaked at $88.1K in Q3 2025. 97 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • Catalyst Funds Management reported no remaining Pliant Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 59,539 Pliant Therapeutics shares in Q4 2025, an estimated $88.1K.
  • Catalyst Funds Management first reported a position in Pliant Therapeutics in Q2 2025 and held it in 2 quarters.
  • Catalyst Funds Management's Pliant Therapeutics position peaked at $88.1K in Q3 2025.
  • 97 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on Catalyst Funds Management's 13F filing for Q4 2025, filed 9 Feb 2026.